Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRA | P18433 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.42 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20190939 | 0.95 | PTPRA (0.48) | PTPRASMN1; SMN2CYP1A2CYP2D6MAPT | |
| SCHEMBL22457372 | 0.95 | PTPRA (0.48) | PTPRASMN1; SMN2CYP1A2CYP2D6MAPT | |
| SCHEMBL20189027 | 0.86 | ITGB3 (0.47) | PTPRAITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL20188361 | 0.85 | HTT (0.45) | PTPRASLC6A9SMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL20188364 | 0.85 | HTT (0.45) | PTPRASLC6A9SMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL20188789 | 0.85 | HTT (0.45) | PTPRASLC6A9SMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL20188691 | 0.83 | KMT2A (0.47) | SMN1; SMN2CYP1A2CYP2D6MAPTTSHR | |
| SCHEMBL20188694 | 0.83 | KMT2A (0.47) | SMN1; SMN2CYP1A2CYP2D6MAPTTSHR | |
| SCHEMBL20188173 | 0.83 | SMN1; SMN2 (0.42) | PTPRAITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL20187735 | 0.82 | PTPRA (0.40) | PTPRASMN1; SMN2CYP1A2CYP2D6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358935-B2 | Prodrugs of lanicemine and their method of use | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-06-14 | — | — | US | claimed |
| US-20200299238-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD. | 2020-09-24 | — | — | US | claimed |
| WO-2018098344-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2018-05-31 | — | — | WO | claimed |
| US-11358935-B2 | Prodrugs of lanicemine and their method of use | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200299238-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD. | 2020-09-24 | — | — | US | disclosed |
| WO-2018098344-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299238-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | GRIN3A, GRIN1, GRM3 | PTPRA 2768/4885ITGB3 3845/4885ITGAV 4536/4885 |
| US-11358935-B2 | Prodrugs of lanicemine and their method of use | GRIN3A, GRIN1, GRM3 | PTPRA 2768/4885ITGB3 3845/4885ITGAV 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.